| Literature DB >> 31880394 |
Juntao Ke1, Xiating Peng1, Shufang Mei1, Jianbo Tian1, Pingting Ying1, Nan Yang1, Xiaoyang Wang1, Danyi Zou1, Yang Yang1, Ying Zhu1, Yajie Gong1, Jing Gong2, Rong Zhong1, Jiang Chang1, Zemin Fang3, Xiaoping Miao1.
Abstract
As promising biomarkers and therapy targets, microRNAs (miRNAs) are involved in various physiological and tumorigenic processes. Genetic variants in miRNA-binding sites can lead to dysfunction of miRNAs and contribute to disease. However, systematic investigation of the miRNA-related single nucleotide polymorphisms (SNPs) for pancreatic cancer (PC) risk remains elusive. We performed integrative bioinformatics analyses to select 31 SNPs located in miRNA-target binding sites using the miRNASNP v2.0, a solid database providing miRNA-related SNPs for genetic research, and investigated their associations with risk of PC in two large case-control studies totally including 1847 cases and 5713 controls. We observed that the SNP rs3802266 is significantly associated with increased risk of PC (odds ratio (OR) = 1.21, 95% confidence intervals (CI) = 1.11-1.31, P = 1.29E-05). Following luciferase reporter gene assays show that rs3802266-G creates a stronger binding site for miR-181a-2-3p in 3' untranslated region (3'UTR) of the gene ZHX2. Expression quantitative trait loci (eQTL) analysis suggests that ZHX2 expression is lower in individuals carrying rs3802266-G with increased PC risk. In conclusion, our findings highlight the involvement of miRNA-binding SNPs in PC susceptibility and provide new clues for PC carcinogenesis.Entities:
Keywords: Chinese population; genome-wide screening; microRNA-binding sites; pancreatic cancer; polymorphisms
Mesh:
Substances:
Year: 2019 PMID: 31880394 PMCID: PMC7011162 DOI: 10.1111/jcmm.14906
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1The flow chart of the integrative bioinformatics analysis in this study. Abbreviations: CHB, Han Chinese in Beijing, China; eQTL, expression quantitative trait loci; EWAS, exome‐wide association study; Gain SNPs, gain‐of‐function SNPs; GTEx, The Genotype‐Tissue Expression; Loss SNPs, loss‐of‐function SNPs; MAF, minor allele frequency; PAAD, pancreatic ductal adenocarcinoma; PC, pancreatic cancer; TCGA, The Cancer Genome Atlas
The characteristics of the study population in Replication Stage
| Case No. (%) | Control No. (%) |
|
| |
|---|---|---|---|---|
| Total | 904 | 1805 | ||
| Gender | ||||
| Male | 725 (80.2) | 1410 (78.1) | 1.57 | 2.11E‐01 |
| Female | 179 (19.8) | 395 (21.9) | ||
| Age, mean (SD) | 60.1 (11.4) | 60.4 (10.7) | 5.75E‐01 | |
| Age group | ||||
| <60 | 407 (45.0) | 866 (48.0) | 2.11 | 1.46E‐01 |
| ≧60 | 497 (55.0) | 939 (52.0) | ||
Abbreviation: SD, standard deviation.
P value was calculated by the t test.
Association between individual SNP and pancreatic cancer risk in Discovery Stage
| SNP | Position | Cases | Controls | OR (95% CI) |
|
|---|---|---|---|---|---|
| HW/HT/HV | HW/HT/HV | ||||
| rs529974 | chr 1:20826910 | 844/97/2 | 3502/397/9 | 1.05 (0.83‐1.31) | 7.03E‐01 |
| rs9259 | chr 1:25168124 | 285/478/165 | 1126/1978/727 | 0.96 (0.86‐1.06) | 4.07E‐01 |
| rs6547016 | chr 2:75888160 | 328/470/145 | 1330/1926/652 | 0.96 (0.86‐1.07) | 4.42E‐01 |
| rs13396556 | chr 2:240900097 | 594/314/35 | 2511/1211/186 | 1.01 (0.89‐1.15) | 8.75E‐01 |
| rs1127898 | chr 3:33186356 | 289/473/181 | 1202/2053/653 | 1.07 (0.96‐1.19) | 2.30E‐01 |
| rs1044147 | chr 4:763077 | 768/162/13 | 3173/700/35 | 1.01 (0.86‐1.20) | 8.81E‐01 |
| rs3733326 | chr 4:57261234 | 545/333/60 | 2242/1415/220 | 1.01 (0.89‐1.13) | 9.23E‐01 |
| rs6844815 | chr 4:90167781 | 277/465/201 | 1127/1990/789 | 1.01 (0.91‐1.12) | 8.94E‐01 |
| rs1298 | chr 5:179289895 | 652/258/32 | 2747/1063/97 | 1.07 (0.93‐1.22) | 3.54E‐01 |
| rs2719236 | chr 8:56924362 | 878/65/0 | 3667/231/2 | 1.17 (0.88‐1.56) | 2.83E‐01 |
| rs2290702 | chr 8:71646980 | 830/112/1 | 3503/397/8 | 1.18 (0.94‐1.46) | 1.48E‐01 |
|
|
|
|
|
|
|
| rs730720 | chr 10:73772762 | 824/118/1 | 3345/560/3 | 0.84 (0.68‐1.04) | 1.16E‐01 |
| rs1678623 | chr 10:73821633 | 710/205/28 | 2863/973/72 | 0.94 (0.81‐1.09) | 4.20E‐01 |
| rs10832948 | chr 11:18628730 | 367/450/126 | 1598/1766/544 | 1.03 (0.93‐1.15) | 5.37E‐01 |
| rs1060709 | chr 13:31903834 | 353/456/134 | 1407/1889/612 | 0.95 (0.86‐1.06) | 3.62E‐01 |
| rs1051332 | chr 13:52507720 | 371/436/135 | 1528/1850/527 | 1.02 (0.92‐1.14) | 6.67E‐01 |
| rs4785920 | chr 16:3000016 | 344/446/153 | 1339/1923/646 | 0.95 (0.85‐1.05) | 2.93E‐01 |
| rs6944 | chr 16:10622895 | 264/568/111 | 1071/2389/448 | 0.99 (0.87‐1.11) | 8.01E‐01 |
| rs2279875 | chr 16:57610832 | 421/426/96 | 1805/1745/358 | 1.07 (0.96‐1.20) | 2.35E‐01 |
| rs3743599 | chr 16:75646576 | 533/368/42 | 2355/1334/219 | 1.08 (0.96‐1.22) | 1.95E‐01 |
| rs1946482 | chr 16:89762410 | 411/437/95 | 1681/1888/339 | 1.01 (0.91‐1.14) | 8.04E‐01 |
| rs11062 | chr 17:1683012 | 267/460/216 | 1167/1897/844 | 1.06 (0.96‐1.17) | 2.73E‐01 |
| rs1582 | chr 19:44830892 | 465/370/105 | 1979/1580/309 | 1.11 (0.99‐1.24) | 6.82E‐02 |
| rs1806940 | chr 20:35945174 | 578/327/38 | 2389/1331/186 | 0.98 (0.86‐1.11) | 7.19E‐01 |
| rs1046612 | chr 20:43996189 | 567/322/50 | 2322/1369/184 | 1.01 (0.90‐1.14) | 8.50E‐01 |
| rs747948 | chr 20:60964301 | 732/198/13 | 3050/824/34 | 1.07 (0.91‐1.26) | 4.00E‐01 |
| rs5752330 | chr 22:26859942 | 577/328/38 | 2350/1373/185 | 0.97 (0.85‐1.10) | 6.11E‐01 |
All ORs, 95%CIs and P values were adjusted by gender and age group. The nominal significant results were in bold.
Abbreviations: 95% CI, 95% confidence interval; HT, heterozygote; HV, variant homozygote; HW, wild‐type homozygote; OR, odds ratio; SNP, single nucleotide polymorphism.
Association between rs3802266 and pancreatic cancer risk in Replication Stage and Combined Stage
| Replication stage | Combined stage | |||||||
|---|---|---|---|---|---|---|---|---|
| Cases (%) | Controls (%) | OR (95%CI) |
| Cases (%) | Controls (%) | OR (95%CI) |
| |
| rs3802266 | ||||||||
| AA | 410 (46.5) | 910 (51.4) | 1.00 | 834 (46.0) | 2886 (51.4) | 1.00 | ||
| AG | 399 (45.3) | 740 (41.8) |
|
| 828 (45.7) | 2357 (42.0) |
|
|
| GG | 72 (8.2) | 120 (6.8) | 1.33 (0.97‐1.82) | 7.93E‐02 | 151 (8.3) | 372 (6.6) |
|
|
| Dominant model |
|
|
|
| ||||
| Recessive model | 1.22 (0.90‐1.65) | 2.04E‐01 |
|
| ||||
| Additive model |
|
|
|
| ||||
All the P values were adjusted by gender and age group. The nominal significant results were in bold.
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio.
Figure 2The effect of rs3802266 on miR‐181a‐2‐3p: ZHX2 binding. A, Relative reporter gene activity from vectors pmirGLO bearing 3′UTR of ZHX2 with the rs3802266‐A allele (pmirGLO‐rs3802266‐A) or rs3802266‐G allele (pmirGLO‐rs3802266‐G) in BxPC‐3 and PANC‐1 cells. B, Relative reporter gene activity of the pmirGLO‐rs3802266‐A and pmirGLO‐rs3802266‐G constructs cotransfected with miR‐181a‐2‐3p into BxPC‐3 and PANC‐1 cells. C, Relative reporter gene activity of the pmirGLO‐rs3802266‐A and pmirGLO‐rs3802266‐G constructs cotransfected with miR‐181a‐2‐3p and its specific inhibitor into BxPC‐3 and PANC‐1 cells. Firefly luciferase/Renilla luciferase were calculated and normalized to blank or corresponding negative controls as relatively luciferase activity. Results were shown as means ± SD from three experiments, each with three replicates. Differences between groups were analysed using two‐sided t tests. *P < .05, **P < .01, ***P < .001. Abbreviations: A, pmirGLO‐rs3802266‐A; G, pmirGLO‐rs3802266‐G; i, inhibitors of miR‐181a‐2‐3p; m, miR‐181a‐2‐3p; nc, negative control
Figure 3eQTL analyses on rs3802266 and ZHX2 in pancreas tissues based on GTEx data. ***P < .001